Impact of Dexmedetomidine on Sleep Quality

PHASE4CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

January 16, 2020

Study Completion Date

February 18, 2020

Conditions
ElderlySurgeryAnalgesiaDexmedetomidineComplication,PostoperativeSleep Quality
Interventions
DRUG

Dexmedetomidine

Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.

DRUG

Placebo

Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT03117790 - Impact of Dexmedetomidine on Sleep Quality | Biotech Hunter | Biotech Hunter